- Records
- 19
- Recruiting
- 11
- Recruiting sites
- 613
- Countries
- 18
ClinicalTrials.gov registry snapshot / 2026-07-24Peptide trials,
Peptide trials,
without the maze.
Search every official registry record matched to 13 tracked peptide and next-generation weight-loss programs. Find current status, phase, enrollment, countries, US states, recruiting cities, postal areas, completion timing, and the direct NCT source.
268unique NCT records
13named programs
53countries represented
1,840recruiting cities
11registry result modules
Recruiting footprint by program
Study status is not drug rank.
Bar length shows registry-listed sites individually marked Recruiting. Larger programs can create larger counts. This does not compare efficacy, safety, approval odds, sponsor quality, or enrollment availability.
- Records
- 52
- Recruiting
- 10
- Recruiting sites
- 170
- Countries
- 7
- Records
- 37
- Recruiting
- 10
- Recruiting sites
- 73
- Countries
- 3
- Records
- 24
- Recruiting
- 10
- Recruiting sites
- 935
- Countries
- 28
- Records
- 27
- Recruiting
- 6
- Recruiting sites
- 1,581
- Countries
- 36
- Records
- 30
- Recruiting
- 5
- Recruiting sites
- 155
- Countries
- 6
- Records
- 8
- Recruiting
- 4
- Recruiting sites
- 339
- Countries
- 23
- Records
- 31
- Recruiting
- 3
- Recruiting sites
- 774
- Countries
- 34
- Records
- 15
- Recruiting
- 3
- Recruiting sites
- 3
- Countries
- 1
- Records
- 34
- Recruiting
- 2
- Recruiting sites
- 450
- Countries
- 27
- Records
- 9
- Recruiting
- 2
- Recruiting sites
- 4
- Countries
- 3
- Records
- 9
- Recruiting
- 1
- Recruiting sites
- 8
- Countries
- 1
- Records
- 5
- Recruiting
- 0
- Recruiting sites
- 0
- Countries
- 0
Official registry finder
Filter the exact records.
Search names, former codes, NCT IDs, sponsors, interventions, conditions, cities, and postal codes. Filtered URLs are shareable but intentionally excluded from search indexing so this page remains the canonical source.
19matching registry records
Snapshot timestampJuly 24, 2026 at 9:00 AM UTC
| Program and record | Status | Phase and enrollment | Locations | Primary completion | Registry update | Source |
|---|---|---|---|---|---|---|
| A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or OverweightNCT06143956 / Eli Lilly and Company | RecruitingVerified 2026-07 | Phase 21,481 estimated | 47 recruiting54 listed / 2 countries | Sep 2027estimated | Jul 20, 2026ClinicalTrials.gov | Open NCT06143956 ↗ |
| A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 DiabetesNCT07215559 / Eli Lilly and Company | RecruitingVerified 2026-07 | Phase 2200 estimated | 41 recruiting42 listed / 4 countries | Mar 2027estimated | Jul 17, 2026ClinicalTrials.gov | Open NCT07215559 ↗ |
| A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 DiabetesNCT07282600 / ENLIGHTEN-2 / Eli Lilly and Company | RecruitingVerified 2026-07 | Phase 31,035 estimated | 104 recruiting159 listed / 14 countries | Jan 2028estimated | Jul 17, 2026ClinicalTrials.gov | Open NCT07282600 ↗ |
| A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 DiabetesNCT07321886 / ENLIGHTEN-1 / Eli Lilly and Company | RecruitingVerified 2026-07 | Phase 31,980 estimated | 107 recruiting162 listed / 15 countries | Mar 2028estimated | Jul 17, 2026ClinicalTrials.gov | Open NCT07321886 ↗ |
| Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or OverweightNCT07353931 / ENLIGHTEN-4 / Eli Lilly and Company | RecruitingVerified 2026-07 | Phase 3900 estimated | 95 recruiting161 listed / 15 countries | Mar 2028estimated | Jul 17, 2026ClinicalTrials.gov | Open NCT07353931 ↗ |
| A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or OverweightNCT07369011 / ENLIGHTEN-3 / Eli Lilly and Company | RecruitingVerified 2026-07 | Phase 3800 estimated | 65 recruiting129 listed / 12 countries | Mar 2028estimated | Jul 17, 2026ClinicalTrials.gov | Open NCT07369011 ↗ |
| A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly IncretinNCT07392190 / ENLIGHTEN-6 / Eli Lilly and Company | RecruitingVerified 2026-07 | Phase 3900 estimated | 108 recruiting173 listed / 13 countries | Jun 2028estimated | Jul 17, 2026ClinicalTrials.gov | Open NCT07392190 ↗ |
| A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers.NCT07401862 / Eli Lilly and Company | RecruitingVerified 2026-06 | Phase 136 estimated | 3 recruiting3 listed / 2 countries | Mar 2027estimated | Jun 4, 2026ClinicalTrials.gov | Open NCT07401862 ↗ |
| A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal FunctionNCT07426380 / Eli Lilly and Company | RecruitingVerified 2026-03 | Phase 128 estimated | 2 recruiting2 listed / 1 countries | Oct 2026estimated | Mar 13, 2026ClinicalTrials.gov | Open NCT07426380 ↗ |
| A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or OverweightNCT07589608 / Eli Lilly and Company | RecruitingVerified 2026-06 | Phase 2400 estimated | 40 recruiting40 listed / 1 countries | Sep 2027estimated | Jun 24, 2026ClinicalTrials.gov | Open NCT07589608 ↗ |
| A Study of Eloralintide (LY3841136) in Participants With Overweight or ObesityNCT07665879 / Eli Lilly and Company | RecruitingVerified 2026-07 | Phase 1115 estimated | 1 recruiting2 listed / 2 countries | Aug 2027estimated | Jul 16, 2026ClinicalTrials.gov | Open NCT07665879 ↗ |
| A Study of Eloralintide (LY3841136) in Healthy ParticipantsNCT07701083 / Eli Lilly and Company | Not yet recruitingVerified 2026-07 | Phase 158 estimated | 0 recruiting2 listed / 1 countries | Oct 2026estimated | Jul 14, 2026ClinicalTrials.gov | Open NCT07701083 ↗ |
| A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 DiabetesNCT06603571 / Eli Lilly and Company | Active, not recruitingVerified 2026-07 | Phase 2367 actual | 0 recruiting52 listed / 2 countries | Jul 1, 2026actual | Jul 17, 2026ClinicalTrials.gov | Open NCT06603571 ↗ |
| A Study of LY3841136 in Healthy and Overweight ParticipantsNCT05295940 / Eli Lilly and Company | CompletedVerified 2024-03 | Phase 1148 actual | 0 recruiting3 listed / 1 countries | Jan 25, 2024actual | Apr 1, 2024ClinicalTrials.gov | Open NCT05295940 ↗ |
| A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or OverweightNCT06230523 / Eli Lilly and Company | CompletedVerified 2026-05Registry results posted | Phase 2263 actual | 0 recruiting43 listed / 1 countries | May 30, 2025actual | Jun 24, 2026ClinicalTrials.gov | Open NCT06230523 ↗ |
| A Study of LY3841136 in Japanese Participants With Obesity or OverweightNCT06297616 / Eli Lilly and Company | CompletedVerified 2026-01 | Phase 1128 actual | 0 recruiting3 listed / 1 countries | Nov 21, 2025actual | Jan 16, 2026ClinicalTrials.gov | Open NCT06297616 ↗ |
| A Study of LY3841136 in Overweight and Obese ParticipantsNCT06345066 / Eli Lilly and Company | CompletedVerified 2025-10 | Phase 196 actual | 0 recruiting3 listed / 1 countries | Sep 29, 2025actual | Oct 15, 2025ClinicalTrials.gov | Open NCT06345066 ↗ |
| A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or ObesityNCT06916065 / Eli Lilly and Company | CompletedVerified 2026-01 | Phase 1188 actual | 0 recruiting3 listed / 1 countries | Jan 19, 2026actual | Jan 30, 2026ClinicalTrials.gov | Open NCT06916065 ↗ |
| A Study of Eloralintide (LY3841136) in Chinese Participants With Obesity or OverweightNCT06916091 / Eli Lilly and Company | CompletedVerified 2025-11 | Phase 130 actual | 0 recruiting1 listed / 1 countries | Sep 9, 2025actual | Nov 19, 2025ClinicalTrials.gov | Open NCT06916091 ↗ |
Recruiting location footprint
Country and US state routes.
Counts are site observations across registry records, not unique facilities. The same research center can appear in multiple studies. Open the exact NCT record before treating a location as current.
Clinical trial finder FAQ
Status, location, and enrollment are different fields.
These answers prevent the most common registry-search errors before a reader follows an official source.
Are any Retatrutide clinical trials recruiting?
Yes. This 2026-07-24 snapshot contains 2 Retatrutide registry records with an overall Recruiting status and 450 listed sites individually marked Recruiting. Overall status does not mean every site is open, and neither status establishes eligibility or enrollment. Open the exact NCT record and verify the individual location before contacting a study team.
How do I find a peptide clinical trial near me?
Enter a city or postal code, optionally add a country or US state, and then open the exact ClinicalTrials.gov record. This finder retains location rows individually marked Recruiting but omits facility and personal contact fields. Confirm current recruitment, eligibility, official contact route, and travel requirements on the registry. Peptide Local does not enroll participants.
Does Recruiting mean I can join the trial?
No. Recruiting is a registry status, not an eligibility decision or appointment. A study can be recruiting overall while some listed locations are not yet recruiting, active but closed, completed, suspended, or missing a current site status. The study team applies the protocol's eligibility and consent process.
Are the drugs in this clinical trial finder FDA approved?
A ClinicalTrials.gov record is not FDA approval. The finder covers investigational programs and can also include studies involving components or comparators with separate regulatory histories. Approval must be verified on the exact FDA label or regulator record, not inferred from a phase, sponsor, trial result, or recruiting status.
Why do only some registry records show posted results?
11 of 268 records in this snapshot expose a ClinicalTrials.gov results module. A record without posted registry results can still have a publication or sponsor announcement elsewhere, while a posted module still requires careful interpretation. Results availability is not a quality rank.
How current is the peptide clinical trial data?
The registry data timestamp is July 24, 2026 at 9:00 AM UTC. The refresh workflow searches exact intervention names and aliases, deduplicates by NCT ID, preserves multi-program studies, and stores overall and individual-site status separately. Registry fields can change after that timestamp, so the direct source remains authoritative for enrollment decisions.
Evidence boundary
A registry finder, not an enrollment service.
A dated transformation of ClinicalTrials.gov intervention-search records for thirteen named Peptide Local pipeline programs. Study sponsors or investigators submit and maintain registry records. Overall status, individual-site status, enrollment, locations, completion dates, and results availability can change. Recruiting status does not establish eligibility, enrollment, treatment access, regulatory approval, routine availability, or a favorable benefit-risk conclusion.
Peptide Local omits personal contact details and does not screen participants, recommend a protocol, interpret eligibility, arrange treatment, or authenticate commercial products that reuse an investigational program's name.
Read the official API documentation ↗Understand evidence categories →